



18. MDR-TB management: new approaches
Friday, 31 October 2014, 12:45-14:15

Chairs: Lucy Chesire (Kenya), John Watson (UK)

Section: Tuberculosis

- OAP-336-31** **Resistance to ethambutol, pyrazinamide, streptomycin and second-line drugs amongst MTB strains susceptible to isoniazid and rifampicin by the MODS assay**
 12:45-12:55
 A Mendoza, A Alarcon, E Castillo, A San Miguel, E Leo, L Asencios, N Quispe, D Moore (*Peru, UK*)
- OAP-337-31** **Association between regimen composition and sputum culture conversion in patients with multidrug-resistant tuberculosis**
 12:55-13:05
 C Yuen, E Kurbatova, J Ershova, T Dalton, P Cegielski, and Global Petts Investigators (*USA*)
- OAP-338-31** **Mycobacterium tuberculosis resistance to bedaquiline**
 13:05-13:15
 K Andries, C Villellas, N Coeck, N Lounis, B De Jong, A Koul (*Belgium*)
- OAP-339-31** **A single-tube single-color assay for all allelic variants of the first line gene targets inhA, katG and rpoB that cause MDR-TB**
 13:15-13:25
 W Wangh, J Rice, K. Pierce, V Allerheiligen, M Eckart, D Hain (*USA, Germany*)
- OAP-340-31** **Treatment outcomes in a large cohort of patients with drug-resistant tuberculosis co-infected with the HIV**
 13:25-13:35
 M Bastard, M Bonnet, T Dlamini, K Kimenye, A Hayrapetyan, . Msf Tb Advisory Group, F Varaine, E Sanchez-padilla (*France, Switzerland, Swaziland*)
- OAP-341-31** **Dose-ranging activity of clofazimine in the mouse model of tuberculosis chemotherapy**
 13:35-13:45
 D Almeida, N Ammerman, C Moodley, B Ncgobo, R Swanson, A Dorasamy, J Adamson, J Grosset (*South Africa, USA*)
- OAP-342-31** **The individual-tailored treatment regimens for multidrug-resistant tuberculosis**
 13:45-13:55
 T Ivanushkina, S Borisov, N Litvinova (*Russian Federation*)
- OAP-343-31** **Association of previous treatment history with treatment outcome among patients with multidrug-resistant tuberculosis**
 13:55-14:05
 P Cegielski, J Ershova, C Kvasnovsky, E Kurbatova, T Dalton, C C Contreras, J Campos Caoili, and Global Petts Investigators (*USA, UK, Peru, Philippines*)
- 14:05-14:15 Discussion